Immunome Set to Release Q4 Earnings Amid Analyst Speculation

Immunome (NASDAQ: IMNM) is poised to announce its fourth quarter earnings for the fiscal year 2025 on March 18, 2025, before the market opens. Analysts project the company will report a loss of ($0.64) per share, alongside estimated revenues of $0.785 million for the quarter. The earnings call is scheduled for 3:00 PM ET on March 3, 2026, allowing investors to gain further insights into the company’s financial performance.

In its previous earnings report released on March 3, 2025, Immunome reported earnings per share of (0.75), falling short of analyst expectations which had anticipated ($0.65) per share. The company also recorded a negative return on equity of 57.61% and a staggering net margin of (1,687.08%). Looking ahead, analysts forecast a loss of ($2) per share for the current fiscal year and further declines to ($3) per share for the following year.

The stock has recently seen a downturn, trading down 3.0% at $20.36 on Monday. With a market capitalization of $2.30 billion, the company’s price-to-earnings ratio stands at -8.41, accompanied by a beta of 2.12. The stock’s performance has varied significantly over the past year, reaching a low of $5.15 and a high of $27.65.

Institutional and Insider Trading Activity

Recent trading activity indicates a shift among institutional investors regarding Immunome. T. Rowe Price Investment Management Inc. has increased its stake in the company by 59.4%, now owning 13,421,987 shares valued at approximately $288.3 million after acquiring an additional 5,003,824 shares in the last quarter. Similarly, Invesco Ltd. raised its holdings by 382.1%, now possessing 270,065 shares worth $5.8 million after adding 214,049 shares.

Wellington Management Group LLP also made a significant move, increasing its holdings by 267.8% to 934,463 shares valued at $20.07 million. These changes have contributed to institutional investors and hedge funds now holding 44.58% of Immunome’s stock.

Analysts’ Ratings and Price Targets

Several equity research analysts have adjusted their price targets for Immunome in light of recent developments. Evercore recently raised its target from $18.00 to $40.00, rating the stock as “outperform.” Conversely, Wall Street Zen downgraded its rating from “hold” to “sell.” Lake Street Capital also increased its target price from $22.00 to $32.00, maintaining a “buy” rating.

Craig Hallum has joined the conversation, boosting its price target from $33.00 to $36.00, also assigning a “buy” rating. Currently, ten analysts have rated the stock as a “buy,” while one has issued a “sell” rating. According to MarketBeat, the average rating stands at “Moderate Buy” with an average price target of $33.45.

About Immunome

Immunome, Inc. is a clinical-stage biotechnology company focused on pioneering antibody-based therapies for oncology and infectious diseases. The firm utilizes a proprietary platform that explores the natural B-cell repertoire of patients with active diseases to identify fully human monoclonal antibodies with unique mechanisms of action. This innovative approach aims to discover antibodies that engage the immune system in ways overlooked by traditional methods, potentially leading to therapies with enhanced efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is an emerging multi-antibody cocktail currently undergoing early-stage clinical trials targeting breast cancer antigens. As Immunome prepares for its upcoming earnings announcement, stakeholders will be keenly observing the results and any strategic directions indicated during the call.